Addressing Unmet Needs in Mantle Cell Lymphoma With CAR T Therapy: Anita Kumar, MD

Video

The medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, about efforts made to address areas of unmet need in mantle cell lymphoma.

Kumar discussed how challenges still exist in treating patients with MCL who harbor p53 mutations, blastic disease, and primary refractory disease, as well as efforts are currently underway to identify which therapies may have activity in these subsets. Recently, data with brexucabtagene autoleucel (formerly KTE-X19; Tecartus) suggest that the CAR T-cell therapy can improve efficacy, even in high-risk subsets, Kumar says.

Because remissions are often shorter with standard chemotherapy/immunotherapy regimens, as well as novel targeted therapies, patients who experience early relapse, harbor p53 mutations, or have blastic disease should be referred to a specialized center with access to CAR T-cell therapy, Kumar concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.